Bioeq and Zydus Lifesciences announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates has entered into a partnership with Bioeq, for the licensing, supply and commercialisation of Bioeq`s Vascular Endothelial Growth Factor (VEGF) inhibitor NUFYMCO, an interchangeable biosimilar of Lucentis (Ranibizumab) for the US market.

The Biologics License Application (BLA) for NUFYMCO has been approved by the US Food and Drug Administration (FDA) on 18 December, 2025. This transaction marks an expansion of Zydus' US biosimilar business, following its recent partnership with Formycon AG for a biosimilar of Keytruda (Pembrolizumab).

Under the terms of this agreement, Bioeq will be responsible for the development, manufacturing, registration and supply of the finished product, while Zydus will be responsible for the commercialisation of NUFYMCO in the US market.

Speaking on the development, Dr Sharvil Patel, Managing Director, Zydus Lifesciences, said, "We are happy to collaborate with Bioeq to bring an interchangeable biosimilar to Lucentis (Ranibizumab) in the US market. Through this partnership, we will leverage our combined expertise and resources to accelerate organisational growth while ensuring maximum value to patients through an expanded access to affordable ophthalmology care."

Dr Thiemo Schreiber, Vice President, Commercial, Bioeq, stated, "We are excited about the regulatory approval of NUFYMCO by US FDA as an interchangeable biosimilar of Lucentis (Ranibizumab). This latest addition to our portfolio reflects Bioeq's advanced expertise in developing complex biosimilar medicines for highly regulated markets. Our partnership with Zydus will leverage its extensive distribution network and strong sales and marketing capabilities across the US to broaden treatment options for patients. We are committed to delivering high-quality, affordable therapies and look forward to this collaboration tailored to driving innovation and improving healthcare accessibility."

The total addressable market opportunity for biosimilar Ranibizumab in the US is approximately USD 210 million as per IQVIA MAT Sep 2025.